YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Procrit
Injured by Procrit?
Latest Procrit Drug WarningOn November 30, 2006, reports came out that two studies in this month’s New England Journal of Medicine have called into question the overuse of drugs in the treatment of anemia in kidney patients. Johnson & Johnson’s Procrit and Amgen’s Epogen are the two most popular anemia drugs which are at the center of the controversy, as researchers try to determine whether they’ve been over-prescribed by medical professionals. Sales of anemia drugs are nearing $10 billion annually. Procrit (Generic: Epoetin alfa) was granted approval in 1999 by the FDA.
According to the above studies, Scientists established that anemic kidney patients are susceptible to heart problems or death when aggressively treated with Epogen or other anemia drugs. The drugs are intended to boost hemoglobin in anemic patients, but the increase in hemoglobin is apparently associated with other serious risks. Prior to the arrival of these anemia treatments, patients had to undergo transfusions to keep their red blood cell counts at healthy levels.
These new drugs have been very successful in boosting red blood cell counts, but the fear today is that doctors have become too reliant on the drugs and that they aren’t sufficiently aware of the risks related to boosting hemoglobin (a main component of red blood cells) in kidney patients, which can include heart attack, stroke, and high blood pressure.
Legal help for Procrit Users
If you or a loved has taken Procrit and suffered heart problems or death, please fill out the form at the right for a free case evaluation by a qualified defective drugs attorney.
ProcritRSS Feed
Amgen Ends Controversial Aranesp Marketing Practices
Aug 29, 2008 | Parker Waichman Alonso LLP
The maker of Aranesp is halting marketing practices that critics said encouraged over-use of the anemia drug. Criticism of the policies, in which Amgen paid rebates to doctors for the purchase of Aranesp, had grown along with questions about the drug's safety. Aranesp is an erythropoiesis-stimulating agent (ESA). Two other ESA's, Epogen and Procrit, are also currently available. All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho...
More than 44,000 Vials of Procrit Recalled
Aug 6, 2008 | Parker Waichman Alonso LLP
Procrit is being recalled by Johnson & Johnson subsidiary Ortho Biotech. According to the company's recall notice, the action is necessary because cracks in the necks of a small number of Procrit vials were discovered upon post-manufacturing inspection.The Procrit recall involves approximately 44,292 vials of lot P114942A distributed between April 15, 2008 and July 17, 2008. The recalled Procrit vials were available in the following packaging configurations:Individual...
FDA Forces New Labeling for Procrit, Aranesp and Epogen
Jul 31, 2008 | Parker Waichman Alonso LLP
Federal regulators have decided that the anemia drugs Aranesp, Epogen and Procrit need to have additional safety-related changes to their labels. The changes mandated by the Food & Drug Administration (FDA) would restrict the use of the drugs in some cancer patients.Procrit, Aranesp and Epogen are known as erythropoiesis-stimulating agent (ESA). All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho Biotech under a licensing agreement....
Study Says Genetic Tests May Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Jun 3, 2008 | Parker Waichman Alonso LLP
Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher recently reported that there may be a way to predict which cancer patients are at risk for this devastating side effect.Procrit, Aranesp and Epogen are known as an erythropoiesis-stimulating agent (ESA). All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho Biotech under a licensing agreement. ESAs are a...
Lawmakers Lean on FDA to Police Drug Advertising
May 8, 2008 | Parker Waichman Alonso LLP
Last month, Congress asked the Food and Drug Administration (FDA) to speed its efforts in forcing drug companies to include safety-reporting information in television and radio ads. Now, Congressional Democrats are placing more pressure on the drug industry's direct-to-consumer advertising following increased problems over the marketing of several popular drugs, including Vytorin, Lipitor, and Procrit.Last year, Democrats lost a fight to increase government regulation of TV commercials...
Defective Drugs
Quick Facts
Procrit Reference Guide
Generic Name
Epoetin alfa
Date Approved
1999
Manufacturer
Johnson & Johnson
Status
On the market
Approved Uses
Anemia
Serious Side Effects
Heart attack
Stroke
Death
Seizures
Convulsions
High blood pressure
Related Topics
Heart Attacks
Stroke
Epogen
Diseases
Defective Drugs
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS